Novel Use of Pepinemab and Nivolumab and FOLFIRINOX Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma (Phase Ib/II)

Pancreatic Cancer
Active Trial
David Linehan, MD
University of Rochester


This trial is testing the effectiveness, safety, and tolerability of the novel combination of two drugs (sacituzumab govitecan and pembrolizumab) for patients diagnosed with HR+ / HER2- metastatic breast cancer. Patients will be assigned into two groups: Group 1 will receive sacituzumab govitecan and pembrolizumab; Group 2 will receive sacituzumab govitecan only. This will allow the researchers to see if the addition of pembrolizumab makes the treatment more effective, safe, and tolerable. If the study is successful, it could lead to a new life-prolonging therapy for patients with HR+/HER2- metastatic breast cancer.